首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Nano-Based Drug Approaches to Proliferative Vitreoretinopathy Instead of Standard Vitreoretinal Surgery
【2h】

Nano-Based Drug Approaches to Proliferative Vitreoretinopathy Instead of Standard Vitreoretinal Surgery

机译:基于纳米的药物方法治疗增殖性玻璃体视网膜病变而不是标准的玻璃体视网膜手术

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Proliferative vitreoretinopathy (PVR) has traditionally been managed with vitreoretinal surgery. Although there have been several recent innovations in this surgery to make the retinal approach as uninvasive as possible, the outcomes remain unsatisfactory. Significant complications remain and the complexity of the surgical approach is challenging. The focus of this review was to investigate and discuss the effectiveness of nanomedicine, featuring a wide range of drugs and molecules, as a novel potential treatment for PVR. To date, ocular drug delivery remains a significant issue due to the physiological and anatomical barriers, dynamic or static, which prevent the entry of exogenous molecules. We tried to summarize the nanotechnology-based ophthalmic drugs and new nanoparticles currently under research, with the intention of tackling the onset and development of PVR. The purpose of this review was to thoroughly and analytically examine and assess the potential of nano-based techniques as innovative strategies to treat proliferative vitreoretinopathy (PVR). This study aimed to emphasize the breakthroughs in nanomedicine that provide promising therapeutic options to enhance the results of vitreoretinal surgery and halt disease progression, considering the complexity and difficulty of PVR treatment. The future directions of the nanoparticles and nanotherapies applied to PVR highlight the importance of investing in the development of better designs and novel ophthalmic formulations in order to accomplish a mini-invasive ocular approach, replacing the standard-of-care vitreoretinal surgery.
机译:增殖性玻璃体视网膜病变 (PVR) 传统上通过玻璃体视网膜手术进行治疗。尽管这种手术最近有几项创新,使视网膜入路尽可能无创,但结果仍然不令人满意。严重的并发症仍然存在,手术方法的复杂性具有挑战性。本综述的重点是调查和讨论纳米医学的有效性,纳米医学具有广泛的药物和分子,作为 PVR 的新型潜在治疗方法。迄今为止,由于动态或静态的生理和解剖屏障阻止外源性分子进入,眼部药物递送仍然是一个重要问题。我们试图总结目前正在研究的基于纳米技术的眼科药物和新的纳米颗粒,旨在解决 PVR 的发生和发展。本综述的目的是彻底和分析性检查和评估基于纳米的技术作为治疗增殖性玻璃体视网膜病变 (PVR) 的创新策略的潜力。考虑到 PVR 治疗的复杂性和难度,本研究旨在强调纳米医学的突破,这些突破为提高玻璃体视网膜手术的效果和阻止疾病进展提供了有前途的治疗选择。应用于 PVR 的纳米颗粒和纳米疗法的未来方向强调了投资开发更好的设计和新型眼科制剂的重要性,以实现微型侵入性眼部入路,取代标准护理玻璃体视网膜手术。

著录项

代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号